At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
Dapagliflozin +1 moredrug
Likely dose
Dapagliflozin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Effects of Dapagliflozin on Insulin Resistance and Insulin Secretion in Subjects With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating Dapagliflozin and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 116 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the effects of dapagliflozin on insulin sensitivity
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
CollaboratorsAstra Zeneca, Bristol-Myers Squibb
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartApr 2009
Primary CompletionAug 2010
TodayJul 2026
First PostedJan 29, 2009
Enrollment StartApr 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.4 years ago
Interventions
Dapagliflozindrug
Tablets, Oral, 5 mg, once daily, 12 weeks
Placebodrug
Tablets, Oral, 0 mg, Once daily, 12 weeks